Home LiteratureArticle Details
PMID: 19142989 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Hepatology (Baltimore, Md.) ·Vol. 49 ·No. 3 ·2009-03-00 ·Pages 809-20

Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA, NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix

Abstract

Adult nonalcoholic fatty liver disease (NAFLD) is characterized by absent or mild portal chronic inflammation (CI); in children, portal CI may be predominant. This study correlated clinical features with portal CI. Centrally-graded biopsies and temporally-related clinical parameters from 728 adults and 205 children. From the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) were evaluated. Mild, more than mild and no portal CI were found in 60%, 23% and 16% of adult biopsies and 76%, 14% and 10% of pediatric biopsies. Autoantibodies, and elevated alanine aminotransferase were not associated with portal CI. Clinical features associated with "more than mild" in adults were older age (P < 0.0001), female gender (P = 0.001), higher body mass index (P < 0.0001), elevated insulin levels (P = 0.001), higher homeostasis model assessment of insulin resistance score (HOMA-IR) (P < 0.0001), and medications used for NAFLD (P = 0.0004), diabetes (P < 0.0001), and hypertension (P < 0.0001). "More than mild" in the pediatric biopsies correlated with younger age (P = 0.01), but not with body mass index, insulin or HOMA-IR. In both groups, lobular and portal inflammation scores had no association, but there was an association with definite steatohepatitis (P < 0.0001). Features associated in the adult biopsies with "more than mild" were steatosis amount (P = 0.01) and location (P < 0.0001), ballooning (P < 0.0001), and advanced fibrosis (P < 0.0001). In the pediatric biopsies, "more than mild" was associated with steatosis location (P = 0.0008) and fibrosis score (P < 0.0001), specifically, the portal/periportal fibrosis or greater fibrosis) (P < 0.01). Increased portal CI is associated with many clinical and pathologic features of progressive NAFLD in both adults and children, but not with ALT, autoantibodies, or lobular inflammation. More than mild portal CI in liver biopsies of untreated NAFLD may be considered a marker of advanced disease.

MeSH Terms
Adolescent Adult Age Factors Alanine Transaminase/blood Biopsy Child Chronic Disease Disease Progression Fatty Liver/blood,pathology Female Humans Inflammation/blood,pathology Liver/pathology Liver Diseases/blood,pathology Male Middle Aged Phenotype Sex Factors
Chemicals
Alanine Transaminase
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Brunt Elizabeth M
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA.
Kleiner David E
Wilson Laura A
Unalp Aynur
Behling Cynthia E
Lavine Joel E
Neuschwander-Tetri Brent A
NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix
References (29)
29 references, click to expand
  1. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome.
    Am J Gastroenterol. 2003 Sep;98(9):2064-71 PMID: 14499789
  2. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.
    Hepatology. 1999 Dec;30(6):1356-62 PMID: 10573511
  3. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.
    Semin Diagn Pathol. 2005 Nov;22(4):330-8 PMID: 16939061
  4. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.
    Hepatology. 2008 Aug;48(2):670-8 PMID: 18666225
  5. Nonalcoholic steatohepatitis: an expanded clinical entity.
    Gastroenterology. 1994 Oct;107(4):1103-9 PMID: 7523217
  6. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.
    Am J Gastroenterol. 2006 Feb;101(2):368-73 PMID: 16454845
  7. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Hepatology. 2004 Jan;39(1):188-96 PMID: 14752837
  8. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.
    Am J Gastroenterol. 1999 Sep;94(9):2467-74 PMID: 10484010
  9. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis.
    Hepatology. 2005 Apr;41(4):809-18 PMID: 15793848
  10. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research.
    J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):413-27 PMID: 17033514
  11. Histological assessment of non-alcoholic fatty liver disease.
    Histopathology. 2006 Nov;49(5):450-65 PMID: 17064291
  12. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.
    Gastroenterology. 2007 Jul;133(1):80-90 PMID: 17631134
  13. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Hepatology. 2005 Jun;41(6):1313-21 PMID: 15915461
  14. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
    Hepatology. 1999 Mar;29(3):664-9 PMID: 10051466
  15. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.
    Mod Pathol. 2003 Jan;16(1):49-56 PMID: 12527713
  16. Histopathology of pediatric nonalcoholic fatty liver disease.
    Hepatology. 2005 Sep;42(3):641-9 PMID: 16116629
  17. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.
    Dig Dis Sci. 2003 Nov;48(11):2173-81 PMID: 14705824
  18. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice.
    Hepatology. 2006 Aug;44(2):458-65 PMID: 16871574
  19. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.
    Surgery. 2004 Jan;135(1):48-58 PMID: 14694300
  20. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Hepatology. 2003 Oct;38(4):1008-17 PMID: 14512888
  21. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.
    Hepatology. 2004 Jun;39(6):1647-54 PMID: 15185306
  22. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease.
    Liver. 2001 Aug;21(4):266-71 PMID: 11454190
  23. Two cases from the spectrum of nonalcoholic steatohepatitis.
    J Clin Gastroenterol. 1995 Mar;20(2):127-30 PMID: 7769192
  24. From Mallory to Mallory-Denk bodies: what, how and why?
    Exp Cell Res. 2007 Jun 10;313(10):2033-49 PMID: 17531973
  25. Drugs and steatohepatitis.
    Semin Liver Dis. 2002;22(2):185-94 PMID: 12016549
  26. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond.
    Hepatology. 2000 Jan;31(1):241-6 PMID: 10613753
  27. Liver fibrosis in overweight patients.
    Gastroenterology. 2000 Jun;118(6):1117-23 PMID: 10833486
  28. Portal lymphocytic infiltrate in alcoholic liver disease.
    Hum Pathol. 2002 Dec;33(12):1170-4 PMID: 12514784
  29. Correct homeostasis model assessment (HOMA) evaluation uses the computer program.
    Diabetes Care. 1998 Dec;21(12):2191-2 PMID: 9839117
Article Info
Journal
Hepatology (Baltimore, Md.)
Abbr.
Hepatology
ISSN
1527-3350
Published
2009-03-00
Pages
809-20
Language
English
Region
United States
NLM ID
8302946
PMCID
PMC2928479
Subset
IM
Grants
NIDDK NIH HHS · U01DK061713 · United States
NIDDK NIH HHS · U01 DK061732 · United States
NIDDK NIH HHS · U01DK061731 · United States
NIDDK NIH HHS · U01 DK061731 · United States
NIDDK NIH HHS · U01 DK061718 · United States
NIDDK NIH HHS · U01DK061718 · United States
NIDDK NIH HHS · U01DK061728 · United States
NIDDK NIH HHS · U01 DK061730 · United States
NIDDK NIH HHS · U01 DK061728 · United States
NCRR NIH HHS · M01 RR000065 · United States
NIDDK NIH HHS · U01 DK061738 · United States
NIDDK NIH HHS · U01 DK061734 · United States
NIDDK NIH HHS · U01DK061738 · United States
NIDDK NIH HHS · U01 DK061737 · United States
NIDDK NIH HHS · U01 DK061713 · United States
NCRR NIH HHS · UL1 RR024989 · United States
NIDDK NIH HHS · U01DK061737 · United States
NIDDK NIH HHS · P30 DK056341-08 · United States
NCRR NIH HHS · M01 RR000188 · United States
NIDDK NIH HHS · P30 DK056341 · United States
NIDDK NIH HHS · P30 DK056341-07 · United States
NIDDK NIH HHS · U01DK061732 · United States
NCRR NIH HHS · M01 RR000750 · United States
NIDDK NIH HHS · U01 DK061718-07 · United States
NCRR NIH HHS · M01 RR000827 · United States
NIDDK NIH HHS · U01DK061734 · United States
NIDDK NIH HHS · U01DK061730 · United States
NCRR NIH HHS · M01 RR020359 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]